We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Technopath Showcases Third Party Quality Controls and Quality Control Software Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)
Image: Multichem ID-Covid 19 Quality Controls (Photo courtesy of Technopath Clinical Diagnostics)

Technopath Clinical Diagnostics (Tipperary, Ireland) showcased its third party quality controls and quality control software solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

The event allowed more than 400 exhibiting companies to showcase the latest product innovations, emerging technologies, and research, and provided the opportunity to browse exhibitors in person for the solutions to lab related needs.

Technopath is one of the largest manufacturers of liquid-ready Quality Control globally in compliance with the highest quality standards. At AACC 2021, the company highlighted Multichem, its class leading third party consolidated Quality Control product range which incorporates a greater number of analytes to enable extensive test menu and control product consolidation. The Multichem IA+ control, for example, allows consolidation of the company’s competitors’ immunoassay, cardiac marker, tumor marker and specialty immunoassay controls into one control. This consolidation allows laboratories to simplify their inventory, reduce costs and improve efficiencies.

For instance, Multichem ID-COVID19 controls are the essential independent quality controls designed to test the precision of assays for antibodies IgG and IgM to SARS-CoV-2, to allow clinical laboratories to release patient results with confidence. The company also exhibited its flagship chemistry product, Multichem S Plus (S for Serum) which consolidates over 100 analytes in to a single product. Also on display was Technopath's leading diabetes product, Multichem A1c, which is a third party QC for hemoglobin A1c. Other products displayed at the event included flagship immunoassay product is Multichem IA Plus which consolidates over 90 analytes in to a single product and can replace up to four competitor products in the lab; and its leading urine chemistry control is Multichem U which provides a single product to cover the majority of standard urine chemistry assays, including Microalbumin, which some competitors provide a separate QC product for.

Alomgside its Multichem quality control product range, Technopath also demonstrated its IAMQC Software which provides laboratory managers and technologists with a range of QC software tools to analyze their QC results in real-time. IAMQC Software tools allow users to automate, centralize, standardize and improve QC processes in a laboratory setting. A combination of modules satisfies the varying levels of QC requirements in individual laboratories and are easily tailored to meet different QC management expectations.

Related Links:
Technopath Clinical Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
All-in-One Molecular System
AIO M160
Hematology Consumables
Bioblood Devices

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more